Residency · Residency · Ophthalmology

Thyroid Eye Disease: Pathogenesis and Modern Management

Start here

Alright team, pull up a chair, even if it's just the edge of your consciousness at this ungodly hour. I know you're tired, but pay attention, because Thyroid Eye Disease (TED) is one of those conditions you will see, and often miss, if you're not primed. Imagine a patient, let's call her Ms. Eleanor Vance, who comes into your clinic complaining that her eyes "feel funny." She's been feeling a bit on edge lately, maybe lost a little weight, and you discover she has hyperthyroidism. Now, initially, you might just attribute her eye complaints to general anxiety. But if you look closer, truly look, you might notice her eyelids are a little high, revealing a sliver of sclera above her iris, or that one eye seems to bulge slightly more than the other. This isn't just cosmetic; it’s an immune system gone rogue, mistakenly attacking the tissues behind her eyeballs.

What's happening inside Ms. Vance's orbits is a biological drama. Her immune system, confused by a structural similarity, is targeting the Thyroid Stimulating Hormone receptor (TSH-R) and the Insulin-like Growth Factor 1 receptor (IGF-1R) on cells in her eye socket. These cells, called orbital fibroblasts, normally just do their thing, but when activated by these autoantibodies, they turn into overzealous manufacturers of fat and a gooey substance called hyaluronan (a type of glycosaminoglycan). This expansion of orbital fat and muscle—especially the extraocular muscles that move her eyes—pushes her eyeballs forward, causes inflammation, and can even pinch her optic nerve.

Now, Ms. Vance's disease isn't going to just stay inflamed forever. Thyroid Eye Disease has a natural course, often described by something called the Rundle Curve: an initial active, inflammatory phase, typically lasting 12 to 24 months, followed by a stable, fibrotic phase. The key takeaway here, for Ms. Vance and all your future patients, is that our medical interventions, especially the newer targeted biologic therapies, are most effective during that active inflammatory period. Missing that window means managing the structural damage and scarring left behind, which is often much harder and requires surgery. So, when you see Ms. Vance, think fast: is she in the active phase, or has the storm already passed? That dictates our next moves.

Introduction

Thyroid eye disease (TED), also known as Graves orbitopathy, is the most common cause of proptosis in adults. It is an autoimmune inflammatory condition targeting orbital tissues, primarily extraocular muscles and orbital fat. Recent breakthroughs in understanding pathogenesis have led to targeted biologic therapies that are transforming management.

Epidemiology

Affects approximately 25-50% of patients with Graves disease. Female predominance (5:1), but males tend to have more severe disease. Peak onset: 40-60 years of age. Smoking is the most significant modifiable risk factor, increasing severity 7-8 fold. Can occur with hypothyroidism, euthyroidism, or Hashimoto thyroiditis (euthyroid Graves)

Pathogenesis

Autoimmune Mechanisms

TSH receptor (TSH-R) autoantibodies bind receptors on orbital fibroblasts. IGF-1 receptor (IGF-1R) forms a physical and functional complex with TSH-R on orbital fibroblasts. Activated orbital fibroblasts differentiate into adipocytes and produce hyaluronan (glycosaminoglycans) Resultant tissue expansion causes proptosis, extraocular muscle enlargement, and orbital congestion. CD4+ T-cell infiltration and cytokine release (IL-6, IL-16, TNF-alpha) amplify inflammation.

Rundle Curve

TED follows a self-limited course described by Rundle's curve. Active inflammatory phase (12-24 months) followed by a stable fibrotic phase. Therapeutic intervention is most effective during the active phase.

Clinical Features

Signs and Symptoms

Lid retraction -- most common sign (present in >90%); Dalrymple sign. Proptosis -- Hertel exophthalmometry; asymmetric in 10-15%. Restrictive strabismus -- inferior rectus most commonly affected, causing hypotropia and diplopia. Periorbital edema, chemosis, conjunctival injection. Lid lag (von Graefe sign) on downgaze. Compressive optic neuropathy -- occurs in 3-5%; may present without significant proptosis ("lipogenic" variant)

Clinical Activity Score (CAS)

Seven-point scoring system (active if >= 3/7):

Imaging

CT orbit (axial and coronal): fusiform extraocular muscle enlargement with tendon sparing, increased orbital fat volume, apical crowding. MRI orbit: T2-weighted sequences differentiate active edematous muscle (hyperintense) from chronic fibrotic muscle (hypointense)

Management

Medical Therapy

Smoking cessation -- critical first step. Selenium supplementation (100 mcg twice daily) -- shown to improve mild TED in EUGOGO trial. Intravenous methylprednisolone -- standard for moderate-to-severe active TED (cumulative dose not exceeding 8 g) Mycophenolate mofetil -- steroid-sparing agent with evidence from EUGOGO trials. Teprotumumab -- anti-IGF-1R monoclonal antibody; FDA-approved 2020; significant reduction in proptosis and CAS in OPTIC trial. Tocilizumab -- anti-IL-6R antibody; second-line biologic option.

Surgical Rehabilitation (Sequential Approach)

Performed after disease stabilization (inactive phase):

Orbital decompression -- for persistent proptosis or compressive optic neuropathy (balanced medial/lateral wall approach preferred) Strabismus surgery -- adjustable sutures; large recessions on tight muscles. Eyelid surgery -- retraction repair (Muller muscle excision, lower lid spacer grafts), blepharoplasty.

Emergent Management

Compressive optic neuropathy: high-dose IV steroids; urgent orbital decompression if no response within 1-2 weeks. Corneal decompensation from severe proptosis: aggressive lubrication, tarsorrhaphy, decompression.

Key Clinical Pearls

TED can occur without hyperthyroidism; always consider the diagnosis in unexplained proptosis or strabismus. Compressive optic neuropathy may occur without severe proptosis due to apical fat expansion. Teprotumumab has revolutionized medical management but carries risks including hearing loss and hyperglycemia. Surgical rehabilitation follows a strict sequence: decompression, then strabismus, then eyelid surgery. Radioactive iodine therapy may worsen TED; concurrent steroid prophylaxis is recommended.

References

1. Douglas RS, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
2. Bartalena L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines. Eur J Endocrinol. 2021;185(4):G43-G67.
3. Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016;375(16):1552-1565.
4. Rootman DB. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63(1):86-104.

For the intern

At 3am, thyroid eye disease (TED) rarely presents emergently unless there's compressive optic neuropathy—decreased vision with relative afferent pupillary defect (RAPD), color desaturation, or visual field loss. In that case, start IV methylprednisolone 1g immediately and call ophthalmology urgently for possible orbital decompression. Severe exposure keratopathy needs aggressive lubrication and urgent consultation. Most TED patients presenting with diplopia, proptosis, or lid retraction can be evaluated during daylight hours once you've documented visual acuity, checked for RAPD, and ensured they can close their eyes enough to protect the cornea. Check thyroid function tests and refer to ophthalmology within days for active disease (Clinical Activity Score assessment) or weeks for stable chronic changes.

Common pitfalls

• Missing compressive optic neuropathy in patients without dramatic proptosis—the "lipogenic" variant with apical fat expansion causes vision loss without obvious bulging eyes. Always check color vision and RAPD, not just Hertel measurements.
• Assuming all proptosis is TED—unilateral cases need orbital imaging to exclude tumors, especially if atypical features present (pain, young age, no thyroid history).
• Ordering radioactive iodine for Graves disease without ophthalmology clearance—this worsens TED unless steroids are given prophylactically. Coordinate endocrine and eye management.
• Operating too early—surgical rehabilitation must wait until disease is inactive for 6+ months, or you'll chase changing measurements and poor outcomes.

Make it stick (one 80-word vignette)

A 52-year-old woman with a history of Graves disease, well-controlled on methimazole, presents with new-onset vertical diplopia and a feeling of "pressure behind my eyes." On exam, she has bilateral upper eyelid retraction, mild proptosis, and conjunctival injection. Her right eye is slightly hypodropic. Her visual acuity is 20/20 in both eyes, but she reports mild pain with eye movement. You notice she carries a pack of cigarettes. This constellation of symptoms points directly to active thyroid eye disease, highlighting the common presentation and a key modifiable risk factor.

If you remember one thing

Thyroid eye disease is an autoimmune condition primarily affecting orbital tissues, often manifesting as proptosis, double vision, and lid retraction. Early recognition and tight control of thyroid function, along with smoking cessation, are crucial for managing this potentially sight-threatening condition.

Read this lecture as Markdown